Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Combination Details

General Information of the Combination (ID: C79198)
Name Gamma tocotrienol + Atorvastatin + Celecoxib
    Click to Show/Hide the Each NP or Drug Information of This Combination
Name Gamma tocotrienol   NP Info     Drug Info 
Structure
Name    Drug Info 
Structure
Disease
Colon cancer [ICD-11: 2B90]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    Molecule(s)
                    Regulation
Up-regulation Cleavage CASP3  Molecule Info 
Pathway MAP
Up-regulation Cleavage PARP1  Molecule Info 
Pathway MAP
                    Biological
                    Regulation
Induction Cell cycle arrest in G0/G1 phase
Increase DNA fragmentation
                    In-vitro Model HT29 CVCL_A8EZ Colorectal adenocarcinoma Mus musculus
HCT 116 CVCL_0291 Colon carcinoma Homo sapiens
                    Experimental
                    Result(s)
Atorvastatin with gamma-tocotrienol and celecoxib exhibited a strong synergy against human colon cancer cells in causing cell cycle arrest and apoptosis.
References
Reference 1 Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. Int J Cancer. 2010 Feb 15;126(4):852-63.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China